Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director | May 28, 2026 | June 01, 2026 |
| EXACT SCIENCES CORPEXAS · Entity 56619 | General Manager - Diagnostics | February 19, 2020 | February 21, 2020 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,766 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 11,766 · Balance 11,766 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
EXACT SCIENCES CORP
Report date February 19, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,128 |
Reported balance
After 2020-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-19 · Exercise / conversion · Acquired 3,934 · Balance 24,128 F1: Represents shares of common stock received upon exercise of a stock option award. |
| Common StockSEC Table I · non-derivative | Direct | 37,550 |
Reported balance
After 2020-02-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-19 · Exercise / conversion · Acquired 13,422 · Balance 37,550 F1: Represents shares of common stock received upon exercise of a stock option award. |
| Common StockSEC Table I · non-derivative | Direct | 10,194 |
Reported balance
After 2020-02-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-02-19 · Sale · Disposed 27,356 · Balance 10,194 F2: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. F3: In addition to the shares of Common Stock reported on this Form 4, which total 10,194 shares, Mr. Cole also holds, in the aggregate, an additional 53,377 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.28 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2020-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-19 · Exercise / conversion · Disposed 3,934 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.91 · Expires 2027-01-31 | Direct | 0 |
Reported balance
After 2020-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-19 · Exercise / conversion · Disposed 13,422 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon exercise of a stock option award.
F2: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan.
F3: In addition to the shares of Common Stock reported on this Form 4, which total 10,194 shares, Mr. Cole also holds, in the aggregate, an additional 53,377 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
Kiniksa Pharmaceuticals International, plc
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 7,172 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-29 · Sale · Disposed 3,673 · Balance 11,672 Row 2 · 2026-07-29 · Gift · Disposed 4,500 · Balance 7,172 F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by the Cole Family Trust | 11,794 |
Reported balance
After 2019-11-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-08 · Disposition to issuer · Disposed 27,385 · Balance 11,794 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $753,089 and 12,335 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Cole Family Trust | 0 |
Reported balance
After 2019-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-08 · Disposition to issuer · Disposed 11,794 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer resticted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 9,026 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.05 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 1,888 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $30,130, less applicable tax withholdings, and 493 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.84 · Expires 2024-01-28 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $296,215, less applicable tax withholdings, and 4,851 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $31.12 · Expires 2025-02-13 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 55,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $808,254, less applicable tax withholdings, and 13,238 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16 | Direct | 5,142 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 56,558 · Balance 5,142 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $927,027, less applicable tax withholdings, and 15,184 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 5,142 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 3,935 shares of Exact Sciences common stock with an exercise price of $35.28 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31 | Direct | 17,538 |
Reported balance
After 2019-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-08 · Disposition to issuer · Disposed 38,582 · Balance 17,538 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $624,767 less applicable tax withholdings, and 10,233 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-08 · Disposition to issuer · Disposed 17,538 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 13,422 shares of Exact Sciences common stock with an exercise price of $35.91 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31 | Direct | 29,436 |
Reported balance
After 2019-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-08 · Disposition to issuer · Disposed 22,894 · Balance 29,436 F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $316,752, less applicable tax withholdings, and 5,188 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-08 · Disposition to issuer · Disposed 29,436 · Balance 0 F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 22,528 shares of Exact Sciences common stock with an exercise price of $43.40 per share. |
| Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $72.52 · Expires 2029-01-29 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-08 · Disposition to issuer · Disposed 27,740 · Balance 0 F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 21,230 shares of Exact Sciences common stock with an exercise price of $94.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $753,089 and 12,335 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer resticted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 9,026 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $30,130, less applicable tax withholdings, and 493 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $296,215, less applicable tax withholdings, and 4,851 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $808,254, less applicable tax withholdings, and 13,238 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $927,027, less applicable tax withholdings, and 15,184 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 3,935 shares of Exact Sciences common stock with an exercise price of $35.28 per share.
F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $624,767 less applicable tax withholdings, and 10,233 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 13,422 shares of Exact Sciences common stock with an exercise price of $35.91 per share.
F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $316,752, less applicable tax withholdings, and 5,188 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 22,528 shares of Exact Sciences common stock with an exercise price of $43.40 per share.
F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 21,230 shares of Exact Sciences common stock with an exercise price of $94.76 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2016 Filed Sep 8, 2016 18:36 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 4,000 | $18.89 | $75,560.00 |
DisclosureSEC source: 0001209191-16-140648 · doc4.xml · nonDerivative · entry 1 Cole G Bradley · CIK 0001337798 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.